No abstract available.
Hydroxyurea ; Skin ; Skin Ulcer

No abstract available.
Carbon Dioxide* ; Carbon* ; Foreign Bodies* ; Foreign-Body Reaction ; Granuloma ; Lasers, Gas* ; Lip*

Diabetes is a rapidly increasing heath care problem all over the world due to increased prevalence during past decade. Diabetic nephropathy develops in 25-30% of patients with type 1 diabetes and is the leading cause of end stage renal disease. Diabetic nephropathy is characterized by persistent proteinuria, decline in renal function, hypertension and increased cardiovascular morbidity and mortality. Early detection of diabetic nephropathy risk is an important goal because early diagnosis and treatment prevent advanced renal damage and other diabetic complications. Increased urinary albumin excretion rate is widely accepted as the first clinical sign of diabetic nephropathy. However, reduced glomerular filtration or hypertension could be the first manifestation in some diabetic patients. We need improved markers and predictors of diabetic nephropathy risk. We report a case of diabetic nephropathy and decreased glomerular filtration rate (GFR) without microalbuminuria occcured in type 1 diabetic patient.
Diabetes Complications ; Diabetic Nephropathies* ; Early Diagnosis ; Filtration ; Glomerular Filtration Rate ; Humans ; Hypertension ; Kidney Failure, Chronic ; Mortality ; Prevalence ; Proteinuria

Papuloerythroderma of Ofuji (PEO) is an uncommon entity of unknown etiology, characterized by coalescing erythematous papules sparing skin folds. A number of cases have described the association of this disorder with malignant with pathology, mainly with cutaneous T cell lymphoma. Such reports give rise to the suggestion that PEO may be a precursor of lymphoma or a form of cutaneous T cell lymphoma. We report a case of PEO, which was diagnosed as cutaneous T-cell lymphoma only 2 months after the development of skin lesions, and rapidly progressed. This case suggests the presence of a variant of cutaneous T cell lymphoma with clinical feature of PEO, which is different from mycosis fungoides or S zary syndrome.
Lymphoma ; Lymphoma, T-Cell, Cutaneous* ; Lymphoma, T-Cell, Peripheral ; Mycosis Fungoides ; Pathology ; Skin

Bortezomib (Velcade(R)) is proteasome inhibitor that is used as a first-line therapy for multiple myeloma. It can cause gastrointestinal, hematologic, and neuromuscular side effects, and a cutaneous reaction is one of its common adverse reactions. To date, several bortezomib-induced cutaneous adverse reactions have been reported, including folliculitis-like rash, pruriginous rash, purpuric rash, mouth swelling, stomatitis-mucositis, edema in the lower limbs, telogen effluvium, and vasculitis. In the Korean literature, only one case of vasculitis has been reported earlier. Two patients have presented with multiple plaques on the trunk at our clinic. The lesions developed several days after bortezomib chemotherapy, and disappeared spontaneously in about 1 week. Herein, we report bortezomib-induced drug eruption presenting as multiple plaques on the trunk with a review of the relevant literature.
Drug Eruptions* ; Drug Therapy ; Edema ; Exanthema ; Humans ; Lower Extremity ; Mouth ; Multiple Myeloma ; Proteasome Inhibitors ; Vasculitis ; Bortezomib

Celecoxib (Celebrex(R)) is a nonsteroidal anti-inflammatory drug (NSAID) which inhibits cycloxygenase (COX)-2 selectively. It is widely used in osteoarthritis and rheumatoid arthritis patients because it causes less gastrointestinal injury than conventional NSAIDs. We report a case of erythema multiforme probably induced by this drug. A 63 year old female patient had taken celecoxib for osteoarthritis and 8 days after she developed erythema multiforme on the whole body.
Anti-Inflammatory Agents, Non-Steroidal ; Arthritis, Rheumatoid ; Drug Eruptions ; Erythema Multiforme* ; Erythema* ; Female ; Humans ; Middle Aged ; Osteoarthritis ; Celecoxib

Paraneoplastic pemphigus is a rare, life-threatening disorder associated with an underlying neoplasm, which presents with painful stomatitis and polymorphous skin lesions. Successful diagnosis of paraneoplastic pemphigus can lead to the diagnosis and treatment of the underlying malignancy.However, involvement of the respiratory system is typically unresponsive to treatment. Herein, we report the case of a 44-year-old female diagnosed with paraneoplastic pemphigus with underlying follicular lymphoma treated with a chemotherapy regimen including rituximab. Her skin lesions and underlying lymphoma responded to treatment, but bronchiolitis obliterans continued to progress and resulted in fatal respiratory failure.

Paraneoplastic pemphigus is a rare, life-threatening disorder associated with an underlying neoplasm, which presents with painful stomatitis and polymorphous skin lesions. Successful diagnosis of paraneoplastic pemphigus can lead to the diagnosis and treatment of the underlying malignancy.However, involvement of the respiratory system is typically unresponsive to treatment. Herein, we report the case of a 44-year-old female diagnosed with paraneoplastic pemphigus with underlying follicular lymphoma treated with a chemotherapy regimen including rituximab. Her skin lesions and underlying lymphoma responded to treatment, but bronchiolitis obliterans continued to progress and resulted in fatal respiratory failure.

Background: Infantile hemangioma is the most prevalent benign vascular tumor in children, with propranolol being the first line systemic treatment. However, the efficacy of low dose propranolol has not been studied yet. Objective: This study aims to explore the effectiveness of low dose propranolol in treating infantile hemangioma in Korea. Methods: This study is a single-arm, retrospective cohort study to evaluating the efficacy of low dose propranolol (1 mg/kg/d) in treating infantile hemangioma. We collected data of patient’s demographics, lesion characteristics, duration and dosage of propranolol use, residual scar, and other treatments used. We evaluate treatment response of infantile hemangioma based on changes in the size of the lesion. Initially, patients were prescribed propranolol at 1 mg/kg/d and monitored on a monthly basis. In cases where the dermatologist deemed the treatment response was clinically insufficient, the dosage was increased to 2 mg/kg/d. Results: We analyzed 68 patients diagnosed with infantile hemangioma. A total of 86.76% of the patients (59/68) were exclusively treated with propranolol at 1 mg/kg/d, resulting in complete regression in 38.98% and partial regression in 61.02%. A total of 13.24% of patients (9/68) had their dosage increased to 2 mg/kg/d due to insufficient effectiveness, which led to improved conditions in nearly 90% of these patients. Conclusion Low dose propranolol (1 mg/kg) is effective in treating infantile hemangioma. Low dose propranolol is recommended to be used in combination with other treatments or for patients at high risk of propranolol adverse effects.

Background: Infantile hemangioma is the most prevalent benign vascular tumor in children, with propranolol being the first line systemic treatment. However, the efficacy of low dose propranolol has not been studied yet. Objective: This study aims to explore the effectiveness of low dose propranolol in treating infantile hemangioma in Korea. Methods: This study is a single-arm, retrospective cohort study to evaluating the efficacy of low dose propranolol (1 mg/kg/d) in treating infantile hemangioma. We collected data of patient’s demographics, lesion characteristics, duration and dosage of propranolol use, residual scar, and other treatments used. We evaluate treatment response of infantile hemangioma based on changes in the size of the lesion. Initially, patients were prescribed propranolol at 1 mg/kg/d and monitored on a monthly basis. In cases where the dermatologist deemed the treatment response was clinically insufficient, the dosage was increased to 2 mg/kg/d. Results: We analyzed 68 patients diagnosed with infantile hemangioma. A total of 86.76% of the patients (59/68) were exclusively treated with propranolol at 1 mg/kg/d, resulting in complete regression in 38.98% and partial regression in 61.02%. A total of 13.24% of patients (9/68) had their dosage increased to 2 mg/kg/d due to insufficient effectiveness, which led to improved conditions in nearly 90% of these patients. Conclusion Low dose propranolol (1 mg/kg) is effective in treating infantile hemangioma. Low dose propranolol is recommended to be used in combination with other treatments or for patients at high risk of propranolol adverse effects.